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Flow Cytometric Analysis of Childhood Lenkemias 
R.Z. Yusuf, S. Pervez, S.A. Aziz; M. Khurshid 
Department of Pathology, The Aga Khan Univcrsily Hospilal, Karachi. 
Abstract 
Objective: To collect demographic data for childhood (less than 15 years) leukemias in Karachi, describe the 
accuracy of the cell surface markers routinely used in the flow cytometric analysis of leukemic cells and arrive 
at an ideal panel of antibodies for analyzing leukemic samlples. 
Materials and Methods: Data from 62 consecutive cases of childhood leukemias referred to the Department of 
Pathology. Aga Khan University Hospital, (AKUH) between January 1995 and December 1998 was analyzed 
using Epi Info Version 6. Flow cytometry on all samples was performed using standard protocols. 
Results: The mean age of patients was 8.2 years and 49 (79%) were males. Fifty (81 %) had acute lymphoblastic 
leukemias of which 50% were CD10 positive and 24% CD10 negative Pre-8 cell leukemias. 
Among all Pre B cell All 98% were positive for CD19. 96% for CD22, 89% for HLA-DR and 67% for CD10. Of 
the 10 AML cases, 100% were positive for CD33, 90% for CD13, 80% for CD19 and 70% for HLA-DR. 
Conclusion: The mean age in this study population was significantly higher and percentage of CD10 positive 
Pre-BAll is lower than that in the West. Both these factors might be responsible for the poorer prognosis of these 
patients. It is not possible to specify a minimum or maximum panel of antibodies that should be used for 
phenotyping all cases of childhood leukemias. A certain degree or redundancy is essential in any panel of 
antibodies used for flow cytometry of leukemias (JPMA 51 :133;2001 ). 
Introduction 
Leukemias are the most common cancers in children 
less than 15 years of age in Pakistan 1• Leukemias also 
comprise the majority (40%) of the childhood malignancies 
in the West including United States 2 Therefore, they make 
up the majority of pediatric malignancies in several parts 
of the world. Most of these are fortunately curable3 The 
epidemiology and biology of these tumors, unlike the 
incidence varies from region to region4,5. This makes it 
essential to ascertain the epidemiology and biology of these 
tumors in our population, as has been done elsewhere 6.7. A 
search o fthe past five years of literature reveals very limited 
statistics relevant to Pakistan, in this regard8. To arrive at 
these statistics was one of the objectives of this study. 
Flow cytometric is highly applicable to the detection 
and classification of leukemias because of the ease with 
which single cell suspensions can be made. Composite 
immunophenotypic analysis is essential for classifying 
leukemias once the disease is detected by traditional 
means9. Ongoing efforts to standardize protocols are 
essential to ensure widespread applicability, together with 
improved understanding of the attributes and limitations of 
this technology. 
Flow cytometric analysis of leukemic samples was 
started routinely at The Aga Khan University Hospital, 
Department of Pathology in 1995 since then there has been 
continuous evaluation and revision of the panel of 
antibodies used to analyze leukemic cells. This study also 
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looks at the accuracy of the cell surface markers that have 
been used routinely for analysis of leukemic samples, since 
1995 to arrive at an ideal panel of antibodies for analyzing 
leukemic samples. 
Materials and Methods 
A study question was formulated and a list of all the 
records of leukemias referred to The Department of 
Pathology, between January 1995 and December 1998 was 
generated. Patients in the desired age group (less than 15 
years) were selected and relevant information from their 
records was documented on specially designed data entry 
forms. The data was then entered in Epi. Info Version 6.1. 
Analysis was performed using the same program. Student's 
t test and Chi square test of significancies were performed 
to determine the presence of a significant difference 
between mean age and the percentage ofCD10 positive pre-
S acute lymphoblastic leukemias between this study 
population and Western literature. Alpha value was chosen 
to be 0.05. 
Flow cytometry was performed on all the peripheral 
blood and bone marrow samples by centrifuging 
mononuclear cells from them. These were then stained with 
florescence labeled antibodies (obtained from Becton 
Dickinson, U.S.A.) and run on FACSCAN using cell quest 
software. The same software was used to analyze the flow 
cytom etry data I 0 
CDJ9, CD20, CD22, CDJO, CD3, CDS, CD7, 
CD13, CD33 and HLA-DR were tested on all the cases! I 
133 
C02 was not included in the panel because of the presence 
ofCD3, CDS and CD7, which are all T cell markers as its 
inclusion would have added no new information. CD14, 
CD45, Anti-Kappa, Anti-Lambda, lgG, lgM and CD61 
were markers that were tested on selected cases. Positivity 
of a clone for a specific cell surface marker was defined as 
more than 30% oft he cells staining with the antibody for the 
respective marker. 
Results 
Data from a total of 62 cases of childhood (less than 
15 years) leukemias, on which tlow cytornetry had been 
perfotrned was analyzed. The mean age of patients was 8.2 
years with a standard deviation of 3.9 years. Most of them 
(49/62 or 79%) were males. The site from which the sample 
was taken was reported in 60 (97%) cases. Of these 32 
(53.3%) were peripheral blood and 28 (46.7%) bone 
marrow samples. 
Figure I Flow cytometry ofCDIO positive common prc-B acute lympnobla>tic leukemia 
Figure 2. Flow cytomctry of acute myclobla>tit leuk~mia 
0 CD 1 0 +ve Pn; 8 ALL 0 CD I 0 -ve Pre B All E1 T Cell ALL E1 Mature B Gell ALL 
Fi!,lure :1 lrnmunolog,ic phcnoty 1le~ of acute lyrnphobla-;tic leukemi,"; (ALL) (n· 50) 
Table I. l~ositivity of different cell surfll.cc markers in various classes of k·ukcmias. 
CDI9+ve CD20+ve CD22+ve CDlO+ve C03+ve CD5+ve CD7+ve CD3+vc CD33+vc IILA-DR+vc Total 
cases 
Pre·B ALL 45 21 44 31 3 6 3 41 46 
T-ALL 0 0 0 0 2 3 3 0 0 0 3 
Mature B 0 0 0 0 0 
Cell ALL 
AML 8 0 () II 2 2 9 10 7 10 
Fifty two cases (83.9%) were acute lymphoblastic positive (Figure 1 ), 28.9% were CD I 0 negative Pre-BALL, 
leukemias (ALL). Of these 52 cases, 59.6% were CDJO 5.8% were T-Cell ALL and 1.9% were mature 8-Cell ALL. 
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Table 2. Comparison of pcn:entagc of different subtypes of Acute 
Lymphoblastic Leukemia~. 
Common Pre-B cell ALL 
T eel! ALL 
Our data(%) 
88.5 
5.8 
Mature B cell ALL/others 7.7 
Western data32 ('Yo) 
80 
15 
Ten of the 62 cases were acttte myeloblastic leukemias 
(AML) (Figure 2). Two cases were reported as inconclusive. 
Of the 31 CD I 0 positive cases, the majority (54.8%) were 
detected in bone marrow samples and 45.2% in peripheral 
blood. The frequencies of the various immunophenotypes of 
acute lymphoblastic leukemias are shown in Figure 3. 
The cell surface markers which were positive in each 
immunologic phenotype of ALL and AML are shown in 
Table I. 
Discussion 
The mean age in this study was 8.2 years with a 
standard deviation of 3.9 years. Peak incidence in the 5-9 
years age group in males and the 10-14 year age group in 
females I. In the West the peak age of incidence is 4 years 12 
which is significantly less (p<0.05) than that seen in our 
population. This could be attributed to the late presentation 
of these children in our setting. 
It is established that ALL is more common in males 
than females, in the pediatric populationl,l2,13_ In 
accordance, the majority of our patients were males. Eighty 
four percent of our cases were those of ALL, the remainder 
being AML, which is similar to the results reported 
elsewherel3,1 4. 
A comparison of the immunologic phenotypes of 
ALL in our population and in the West are shown in Table 
2. The frequencies of gross categories are similar but there 
is a paucity of COlO positive Pre-BALL (p<O.OS) in our 
series as compared to the West and Far East15-18 This 
decrease in COlO positive Pre-BALL, (COlO being a good 
prognostic indicatorl5,17J9 could account for the poorer 
prognosis of leukemias in our population 20. 
There was no marked excess of CD I 0 positive cells 
in the bone marrow samples as compared to the peripheral 
blood samples. This corroborates evidence that significant 
homing mechanisms do not seem to be actively involved in 
localizing COlO positive cells to the bone marrow21. 
Since 1995, flow cytometry has routinely been 
performed on leukemic samples at the Department of 
Pathology, AKUH. 
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The following is arl analysis of the accuracy of 
markers commonly used for flow cytometric analysis of 
leukemias at AKUH. The denominator for this analysis is 
60 cases (excluding the two cases which were reported as 
inconclusive). The terms "specificiy" and "sensitivity" are 
not used in the strict statistical sense. Accuracy of various 
markers was calculated by working out the percentage of 
cells which tested positive for the markers which were 
expected biologically, to be present on these cells. This 
method of analysis has been used before, successfully8 
CDI9 was detected on 92% ofB-Cell ALL and 80% 
of AML cases. As shown earlier, CD 19 is not very specific 
to B Cell leukemias10.22 CD20 was positive in 44% of 
cases of B Cell ALL and was not expressed on any non B 
Cell malignancy. Our study confirms that CD20 is less often 
expressed on acute B lineage leukemias than CD19 but is 
more "specific:' for B cell malignanciesl0,23. CD22 was 
found on 90% of the B cell malignancies and on none of the 
non B cell malignancies. A highly "sensitive" and "specific" 
marker, CD 22' s usefulness to detect acute B-lineage 
leukemias is decreased by the fact that it is often dim and is 
more strongly expressed in the cytoplasm of cells than on 
their surface 111.24 67% (31/46) of the cases of Pre B Cell 
ALL were COl 0 positive. This is lower than the percentage 
of CD!O positive Pre-B cell ALL reported in the West and 
this point has been discussed above. CD 1 0 was not detected 
on any case of T cell ALL (as has been reported in 
literature IS_ This could be due to the small number of cases 
ofT cell ALL in our study. We hypothesize that it could also 
be due to the high socio-economic status of the patients 
reporting to the Aga Khan University Hospital since T-ALL 
is more common in the low socio-economic group. 
However our study does not have the power to test this 
hypothesis. 
CD3 was detected on 66.7% of the cases ofT cell 
ALL and 7% of the cases of non T cell malignancies. It is 
hence a "sensitive" and "specific" marker for detecting T 
cell ALL23 Its usefulness is limited by the fact that it is 
uncommonly expressed on the surface ofT-lineage ALL. It 
is almost always present in the cytoplasm of these cellsl0,25_ 
CDS was found on all 3 cases ofT cell leukemias and 12.3% 
of non T cell malignancies. Our study corroborates evidence 
that CDS is specific for T cells and occurs in a great 
majority of cases, the drawback once again being that it is 
dimly expressed 10.26. CD? was seen on 4/46 cases ofPre-8 
cell ALL. This was seen in samples of peripheral blood for 
leukemia analysis, which normally has 80% T lymphocytes. 
This pattern is most likely reactivity to normal circulating 
lymphocytes. CD7 was also found on all cses ofT cell ALL 
and on _14% of cases of non T cell ALL. It is reported in 
literature however, that CD? is found tn cases of AML too 
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and is not as "specific" for T cell ALL as our study 
suggests I 0,27 
CD 13 was found on 90% of cases of AML and 8% 
of non AML cases. CD33 was found on all cases of AML 
and on 2% of non AML cases. Both these markers are hence 
valuable for diagnosis of AML. Since both can occasionally 
be expressed on B or T lineage ALL they should be 
interpreted as strongly suggestive of myeloid leukemia only 
when expressed in the absence of lymphoid associated 
antigensl0,26. Our study confirms previous reports that 
HLA-DR is found in most cases of AML and B lineage 
ALLI0.28 
In conclusion, the epidemiology of acute leukemias 
·in our study population is similar to that reported in the 
West. This has also been shown in another Pakistani 
studies29,30. Late age at presentation and an excess of COlO 
positive cases may lead to poor outcome. 
Regarding flow cytometry, antibodies clearly vary in 
their degree of lineage specificity. Also, many leukemias 
lack one or more antigens expected to be present on normal 
cells of a particular lineage9.10,31 .32. It is hence 
recommended, that a certain degree of redundancy be built 
into a panel for leukemia phenotyping. 
Where possible it is recommended that lineage 
assignment be confirmed with an antibody from a second 
CD cluster which is known to react principally with the 
suspected cell lineage. However, failure to detect the 
confirmatory marker does not exclude the suspected lineage 
since leukemias commonly exhibit loss of various antigens. 
It is hence not possible to specify a minimum or maximum 
pane) that should be used for phenotyping all cases of 
JeukemiaslO,I4,33 
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